Expanding Access to Diabetes Self-Management Training Act of 2025
Summary
HR3826 expands Medicare coverage of diabetes self-management training, removing hour limits and testing virtual delivery. This structurally increases the diagnostically engaged Medicare beneficiary pool, directly benefiting CGM makers ($DXCM, $ABT) and insulin pump manufacturers ($MDT). The bill is early-stage but has a Senate companion and bipartisan sponsorship, and current stock prices for all three tickers are near 52-week lows, potentially discounting this structural catalyst.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR3826 expands Medicare DSMT coverage without appropriation; impact on device makers is via increased patient engagement, not direct funding.
- 2.CGM manufacturers ($DXCM, $ABT) are the most directly exposed beneficiaries — expanded training drives CGM initiation and adherence in Medicare beneficiaries.
- 3.All three tickers are near 52-week lows, suggesting the market may be discounting this structural Medicare-volume catalyst amidst sector-wide medtech weakness.
- 4.Bill is early-stage (referred to committee) with a Senate companion — not imminent but a legitimate catalyst to monitor.
Market Implications
DexCom ($DXCM) at $58.33 and Abbott ($ABT) at $90.74 are both trading near their 52-week lows, with 30-day declines of -7.12% and -11.62% respectively. This sector-wide selloff, driven by GLP-1 disruption fears and macro headwinds, may have created a discounted entry point around a structural Medicare volume catalyst. Medtronic ($MDT) at $79.90 is also near its 52-week low, though its diabetes segment exposure is smaller. If HR3826 gains committee momentum (markup, hearing), the risk/reward for $DXCM and $ABT becomes asymmetric to the upside given the current valuation floors. The causal chain is indirect (DSMT expansion → more engaged patients → higher CGM/pump utilization) but grounded in established clinical and reimbursement patterns where DSMT correlates with device adherence.
Full Analysis
HR3826, the Expanding Access to Diabetes Self-Management Training Act of 2025, was introduced in the House on June 6, 2025 by Rep. Schrier (D-WA) and referred to the Energy and Commerce and Ways and Means Committees. This is an early-stage authorization bill — it does not appropriate any specific dollar amount. The bill amends the Social Security Act to mandate Medicare coverage of an initial 10 hours of DSMT (available until used) plus 2 hours per year, and prohibits CMS from limiting medically necessary training. It also orders the Center for Medicare and Medicaid Innovation to run a virtual DSMT pilot.
The money trail here is indirect: the bill does not authorize a fixed funding pool. Instead, it directs CMS to cover additional DSMT hours under Part B (reimbursement for training services). The cost is borne by the Medicare Trust Fund, increasing per-beneficiary spending on training services. The financial impact on device makers comes through increased patient engagement: patients who receive comprehensive DSMT are more likely to initiate and adhere to CGM and insulin pump therapy. Medicare already covers CGM for all insulin-treated patients, so expanding DSMT expands the addressable patient base for CGM and pump manufacturers who are already Medicare-reimbursed.
Structural winners are pure-play CGM manufacturers DexCom ($DXCM) and Abbott ($ABT), whose entire diabetes businesses benefit from expanded Medicare beneficiary engagement. Medtronic ($MDT) benefits as a pump manufacturer, though its diabetes segment is a smaller portion of its total revenue (~12%). Tandem Diabetes ($TNDM) and Insulet ($PODD) are also beneficiaries but are smaller in Medicare pump market share. The virtual DSMT pilot specifically benefits telehealth platforms, though the bill does not name specific vendors.
Real market data shows all three tickers trading near 52-week lows: $DXCM at $58.33 (52-week range $54.11–$89.98, -7.12% over 30 days), $ABT at $90.74 (52-week range $90.29–$139.06, -11.62% over 30 days), and $MDT at $79.90 (52-week range $78.91–$106.33, -7.79% over 30 days). The sector-wide pullback (medtech has been weak across the board due to GLP-1 disruption fears, macro uncertainty, and China headwinds) may have oversold the Medicare-specific volume driver that HR3826 represents.
Timeline: HR3826 is in Committee referral phase with no scheduled markup. It has a Senate companion (S.1925, referred to Finance Committee) and bipartisan House cosponsors, which improves but does not guarantee passage. The 119th Congress runs through 2026, so committee action and potential floor votes would occur during 2025–2026. Passage probability is moderate — similar diabetes access bills have had difficulty advancing but the bipartisan nature and modest scope (no new funding, only coverage mandate) increase odds.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Expansion of Medicare coverage for diabetes outpatient self-management training (DSMT) removes existing hour limits and mandates a CMS virtual training pilot, structurally increasing the diagnostically engaged Medicare beneficiary pool by removing barriers to training utilization.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must expand DSMT coverage, not limit medically necessary training, and test virtual DSMT model.
What happens
Medicare beneficiaries with diabetes receive additional DSMT hours (initial 10 hours until used, plus 2 hours per year) without the previous cap; the virtual pilot broadens access, particularly for rural/homebound patients. Expanded training utilization correlates with increased CGM initiation and adherence.
Stock impact
DexCom derives ~70% of revenue from US CGM sales, with Medicare beneficiaries representing a significant and growing share due to the 2021 expansion of CGM coverage to all insulin-treated Medicare patients. Broader DSMT access increases the addressable pool of patients prescribed and retained on CGM systems. DexCom's current stock price of $58.33 is near its 52-week low of $54.11, with a 30-day decline of -7.12%, creating a valuation floor around a structural catalyst.
What the bill does
Expansion of Medicare coverage for diabetes outpatient self-management training (DSMT) removes existing hour limits and mandates a CMS virtual training pilot, structurally increasing the diagnostically engaged Medicare beneficiary pool by removing barriers to training utilization.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must expand DSMT coverage, not limit medically necessary training, and test virtual DSMT model.
What happens
Medicare beneficiaries with diabetes receive additional DSMT hours (initial 10 hours until used, plus 2 hours per year) without the previous cap; the virtual pilot broadens access. Expanded training utilization correlates with increased CGM initiation and adherence.
Stock impact
Abbott's FreeStyle Libre is the dominant CGM franchise globally and in the US, including Medicare beneficiaries. Broader DSMT access across the Medicare population drives higher Libre utilization, particularly among non-intensive insulin users now eligible under expanded Medicare criteria. Abbott's current price of $90.74 is near its 52-week low of $90.29, with a 30-day decline of -11.62%, pricing in macro headwinds but discounting Medicare volume catalysts.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Ensuring Patient Access to Critical Breakthrough Products Act
Medical Device Nonvisual Accessibility Act of 2025
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
CAPEX & D SQUARE, A JOINT VENTURE LLC: $23.2M Department of Veterans Affairs Contract
Stop Corporate Inversions Act of 2026
NATIONWIDE HEALTHCARE SOLUTIONS, LLC: $16.9M Department of Health and Human Services Contract
NORTH EAST SOUTH WEST HEALTHCARE SOLUTIONS, LLC: $16.5M Department of Homeland Security Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.